Church of PeptidesSearch
Portrait of Sermorelin
Pilgrims · approved 1990; discontinued 2008

Sermorelin

The Retired Herald

United States

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone that can stimulate pituitary growth-hormone secretion. It has a history of approved diagnostic and pediatric uses, but that history does not establish contemporary wellness claims.

Evidence ladder: Controlled human evidenceEducational record
ClassificationPilgrims
Evidence summaryHistorical approved uses; current products require separate evaluation
OriginUnited States
Scientific record

What the evidence says

Established role or proposed benefit

  • Mimics the first 29 amino acids of GHRH.
  • Can stimulate pituitary growth-hormone release.

Side effects, risks, and limits

  • Geref approvals were withdrawn effective June 18, 2009. In 2013 FDA determined the products were not withdrawn for safety or effectiveness reasons.
  • Contemporary wellness claims are not established by its historical diagnostic and pediatric growth-failure indications.
Doctide’s verdict

The Retired Herald carries authentic historical papers. Doctide reads their dates and indications before accepting the seal: evidence for childhood growth failure does not become evidence for adult rejuvenation simply because the molecule is familiar.

Documented history

Where the real story begins

FDA records distinguish two Geref approvals: a diagnostic product in 1990 and a pediatric growth-failure treatment in 1997. Both were discontinued in 2008, with approvals withdrawn in 2009. In 2013 FDA determined they had not been withdrawn for reasons of safety or effectiveness. Historical source.

United States · approved 1990; discontinued 2008
Book of the Canon · comic scripture

The laboratory legend

Sermorelin presented an old federal seal, then quietly explained that the product had left the market years ago. Doctide created a shelf labeled Formerly Approved Is Not Currently Approved.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. The FDA record covers both diagnostic and pediatric growth-failure indications. FDA determined these products were not withdrawn for safety or effectiveness reasons; that is not a new product approval.

  1. FDA determination on withdrawn Geref products, March 4, 2013

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.